No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DCTH Delcath Systems
- 7.350
- -0.430-5.53%
Close May 28 16:00 ET
204.23MMarket Cap-2805P/E (TTM)
7.780High7.230Low304.58KVolume7.780Open7.780Pre Close2.25MTurnover1.50%Turnover RatioLossP/E (Static)27.79MShares8.50052wk High13.97P/B149.53MFloat Cap2.25052wk Low--Dividend TTM20.34MShs Float7069.999Historical High--Div YieldTTM7.07%Amplitude-9223372036.855Historical Low7.400Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Delcath Systems Announces Appointment of Bridget Martell, Ma, Md to Delcath’s Board of Directors
Retail Investors Who Hold 55% of Delcath Systems, Inc. (NASDAQ:DCTH) Gained 49%, Institutions Profited as Well
Key Insights The considerable ownership by retail investors in Delcath Systems indicates that they collectively have a greater say in management and business strategy 44% of the business is held by
Delcath Systems Is Maintained at Buy by HC Wainwright & Co.
Delcath Systems Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $22
Delcath Systems Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 205.13% HC Wainwright & Co. $20 → $22 Maintains Buy 05/14/2024 246.74% Stephens & Co. → $25 Ini
Delcath Systems: Strong Financials and HEPZATO KIT Growth Prompt Buy Rating and Raised Price Target
Comments
$Delcath Systems(DCTH.US$ Delcath Systems Q1 2024 GAAP EPS $(0.45) Beats $(0.47) Estimate, Sales $3.139M Beat $2.187M Estimate
$Delcath Systems(DCTH.US$ Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
1
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Delcath Systems(DCTH.US$ Delcath Systems Announces $7M Private Placement
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg